MediWound Ltd. - Ordinary Shares (MDWD)

MediWound's Q2 2025 results show mixed performance: $5.7M revenue (+43% QoQ) missed estimates, but shares rose 5% on NexoBrid growth and EscharEx progress.

MDWD stock results show that MediWound missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family

Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after the company announced it received two purchase orders for a total of approximately one million SecureGard syringes for 2024 delivery.

MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.

Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S.

Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.11 per share on revenue of $149.42 million.